美国注册 · 商业咨询 → 生物医药 / 生命科学US-Registered · Consulting → Biopharma / Life Sciences

CPL BIOPHARMA INC.

商业咨询起家 · 稳步拓展至早期医药项目评估From business advisory to early-stage biopharma evaluation

让每一分钱都花得值得。
物有所值 · 物超所值Every dollar well spent.
Value delivered, value exceeded.

CPL BIOPHARMA INC. 前身为美国信息科技有限公司（American Information Technology Inc.），创立于 2023 年 9 月 22 日，2025 年更名为现名。公司专注市场调研、可行性分析与商业模式设计，帮助小微企业避开坑、降低试错成本，并将严谨的咨询能力延伸至生物医药与健康科技领域。

CPL BIOPHARMA INC., formerly American Information Technology Inc., was founded on Sept 22, 2023 and renamed in 2025. We specialize in market research, feasibility analysis and business-model design — helping small businesses avoid costly mistakes, now extending proven methods into biopharma and health tech.

查看核心服务Explore services 查看研究案例See our work

2023 · 09 · 22美国注册成立 · 纽约Registered in the USA · New York

Biopharma laboratory — 🔬 实验室级严谨 · 每一个结论都有证据支撑🔬 Lab-grade rigor · Every conclusion backed by evidence

关于我们About us

CPL BIOPHARMA INC. — 先讲证据，再谈方案CPL BIOPHARMA INC. — Research before recommendations

CPL BIOPHARMA INC. 坚持“稳健、务实、价值优先”：任何项目开始前，先做独立、系统的市场调研；再结合你的资源、团队与成本结构，给出真正可执行的判断 — 帮你避免踩坑、减少试错、降低投入风险。

CPL BIOPHARMA INC. operates on “Prudent · Pragmatic · Value-first”: every engagement starts with independent, systematic market research, then maps your resources, team and cost structure into a truly executable plan — avoiding pitfalls, cutting trial-and-error and lowering investment risk.

📋 透明轻资产运作
方法论可复用、可验证📋 Transparent, asset-light
Reusable, verifiable methods

🧭

价值导向Value-driven

确保每一笔咨询费用都有实质回报，不做空话套话。

Every consulting dollar must return real, measurable value — no empty talk.

🔍

证据先行Evidence-first

市场容量、增长趋势、客户结构、竞争格局与行业风险，全部用数据说话。

Market size, trends, customer segments, competition and risks — all backed by data.

🛡️

稳健合规Prudent & compliant

轻资产、透明化运作，风险识别与合规建议贯穿始终。

Asset-light and transparent, with risk and compliance review throughout.

核心能力Capabilities

四个核心能力，只做算得清账的事Four core capabilities — only what we can underwrite

以下为公司长期沉淀的咨询能力，也是未来服务生物医药项目评估与孵化的基础方法论。

Our long-standing advisory capabilities — and the methodological foundation for future biopharma project evaluation and incubation.

📊

市场情报Market Intelligence

市场规模、竞争格局、客户需求 — 先看清牌桌再上桌。

Sizing, competition, customer needs — read the table before sitting down.

含 · 市场调研与行业分析

incl. market research & industry analysis

🧭

可行性与战略Feasibility & Strategy

可行性、商业模式、进入策略 — 行不行，先算再说。

Feasibility, business models, entry strategy — run the math first.

含 · 商业逻辑与可行性分析、收入模式设计、企业发展规划

incl. feasibility analysis, revenue design, growth planning

💰

财务与运营模型Financial & Operating Model

成本、收入、盈亏平衡、运营模型 — 每一分钱的去向。

Costs, revenue, breakeven, operating models — where every dollar goes.

含 · 成本结构与运营压力分析、运营与组织管理咨询

incl. cost analysis, operations & organization

⚖️

风险与决策支持Risk & Decision Support

风险、合规、Go / No-Go 判断 — 该停就停。

Risks, compliance, go / no-go calls — stop when the math says stop.

含 · 风险识别与合规建议、公司治理结构咨询、问题诊断与解决方案

incl. risk & compliance, governance, diagnostics & solutions

查看完整 9 项服务模块＋Full 9-module list ＋

市场调研与行业分析 — 容量、趋势、客户结构、竞争格局与风险Market research & industry analysis
商业逻辑与可行性分析 — 结合资源与定位，避免误判Business logic & feasibility
成本结构与运营压力分析 — 人力、租金、运营与获客成本Cost & operating-pressure analysis
收入模式与盈利逻辑设计 — 确保商业模式可执行Revenue & profit-logic design
企业发展规划咨询 — 目标、资源配置与增长节奏Growth & strategic planning
公司治理结构咨询 — 架构、流程与制度建设Corporate governance
运营与组织管理咨询 — 流程诊断与效率提升Operations & organization
风险识别与合规建议 — 项目与运营风险规避Risk & compliance guidance
问题诊断与解决方案设计 — 可落地的调整策略Diagnostics & solutions

研究能力实证Research

我们用报告证明方法论Proven methods, documented in reports

以下为公司近年完成的中英文行业调研与企业个案 — 点击卡片可查看脱敏版目录样本（节选）、关键摘录与体量说明。公开版已隐去客户真实名称与地址、人名；完整脱敏版目录与方法说明可在正式咨询时索取（可签 NDA）。

Selected Chinese-English industry and case studies below — click any card for a redacted sample (excerpted contents, key excerpt and size). Client names, addresses and personal names are removed in the public version. Full redacted contents and methodology available upon formal engagement (NDA available).

01 · 行业研究01 · Industry Report

2025 纽约州餐饮行业 · 厨房日用品批发研究报告2025 NY Restaurant & Kitchenware Wholesale Report

市场容量 / 增长趋势 / 客户结构 / 竞争格局 / 风险全覆盖。

Full coverage: sizing, trends, customers, competition and risks.

02 · 行业研究02 · Industry Report

2025 纽约市美容院行业调研报告2025 NYC Beauty Salon Industry Report

门店模型、成本结构、获客与复购逻辑拆解。

Store models, cost structure, acquisition and retention logic.

03 · 行业研究03 · Industry Report

2025 纽约市食品进口行业调研报告2025 NYC Food Import Industry Report

供应链、合规与渠道三维分析，识别高风险环节。

Supply chain, compliance and channel analysis with risk mapping.

04 · 企业个案（已脱敏）04 · Case Study (Redacted)

纽约州餐饮耗材批发企业个案调研（代号 H·Wholesale）NY Foodservice Consumables Wholesaler — Case Study (Codename H·Wholesale)

企业级深度个案：业务诊断 + 可行性 + 发展路径。

In-depth diagnostics, feasibility and growth roadmap.

05 · 企业个案（已脱敏）05 · Case Study (Redacted)

大纽约地区非银行信贷机构个案调研（代号 R·Capital，2025）Greater-NY Non-Bank Lender — Case Study (Codename R·Capital, 2025)

资本与治理视角的项目评估，兼顾商业与合规。

Capital & governance review balancing business and compliance.

工作流程Process

🔍

01 调研01 Research

独立系统取证

Independent evidence

🧮

02 测算02 Modeling

成本·收入·风险

Costs · revenue · risks

🧩

03 设计03 Design

模式·路径·节奏

Model · path · pacing

📋

04 规划04 Planning

可执行方案

Executable plan

🤝

05 陪跑05 Support

调整·优化·复盘

Adjust · refine · review

未来方向Future

从商业咨询，到生物医药与生命科学From business advisory to biopharma & life sciences

CPL BIOPHARMA INC. 将在保留原有咨询能力的基础上，逐步将业务关注方向拓展至生物医药、生命科学、健康科技及相关产业服务 — 采取审慎、合规、分阶段的方式。

CPL BIOPHARMA INC. will build on proven advisory capabilities and gradually expand into biopharma, life sciences, health tech and related industry services — in a prudent, compliant, phased manner.

※ 以下均为探索方向，不代表现有产品、临床项目或监管批准。※ Exploratory directions only — not existing products, trials or approvals.

现在已交付 · 有报告为证Delivered · Evidenced

商业咨询：5 份报告，可查目录Advisory: 5 reports, checkable

市场规模测算（如 32–36 亿美元内部模型估算区间，非官方统计）Market sizing (e.g. $3.2–3.6B internal modeling estimate, not official stats)
成本 / 盈利结构拆解与 SOP 诊断Cost / profit breakdowns & SOP audits
Go / No-Go 决策依据与路线图Go / no-go basis & roadmaps

↑ 回看研究案例目录↑ See case contents

现在可接 · 老方法做新题Available now · Same methods

医药早期项目评估（咨询范畴）Early pharma evaluation (advisory)

适应症规模与支付意愿桌面测算Desk sizing of indications & willingness-to-pay
立项可行性过会材料与资金规划Feasibility packs & funding plans
合规风险清单（非法律意见）Compliance risk lists (not legal advice)

未来探索 · 条件就绪才谈Exploratory · Conditional

研发 / 孵化：四个方向分阶段看R&D / incubation: phased

需团队、资金、合作与合规四项就绪Requires team, funding, partners, compliance
任何阶段设退出标准、可停Exit criteria at every gate
不承诺产品、审批与回报No promise on products, approvals, returns

当前所处：阶段一 · 桌面研究（跟踪方向、积累判断，不投钱）Current phase: Phase 1 · Desk research (track & learn, no capital at risk)

👇 四个探索方向，点击切换 — 每个方向只做能算清账的部分👇 Four exploratory tracks — click to switch; each limited to what we can underwrite

精准医疗 — 先分层，再谈投入Precision medicine — segment first, fund later

延续咨询的“客户分层”功底：先把人群、适应症、支付意愿算清楚，再谈投不投。

Our segmentation discipline applied to populations and indications: size the pool and the willingness to pay before committing a dollar.

适应症与人群规模、支付意愿测算Indication sizing and willingness-to-pay analysis
竞品格局与差异化窗口判断Competitive landscape and differentiation windows
进入 / 放弃的量化门槛，花钱前先写好Go / no-go thresholds, written before spending

细胞与免疫 — 长周期，先算资金账Cell & immuno — fund the long cycle first

细胞技术与肿瘤免疫周期长、投入大：先拆里程碑、再排融资节奏，绝不一次 All-in。

Long-cycle, capital-heavy programs get milestone-based budgets and financing rhythms — never all-in upfront.

按里程碑拆解成本与风险敞口Milestone-based cost and exposure breakdown
融资节奏与现金流安全垫Financing cadence and cash cushions
每阶段退出标准，事先约定Pre-agreed exit criteria at every gate

人工智能辅助研发 — 工具提效，判断守规AI-assisted R&D — tools for speed, evidence for calls

人工智能负责初筛与提效，关键结论必须经人工证据复核与合规审查。

AI handles triage and acceleration; critical conclusions pass human evidence review and compliance checks.

文献、靶点、数据三类初筛Literature, target and data triage
研发流程提效降本测算Measurable efficiency and cost gains
不夸大、不承诺疗效，结论可复核No hype on efficacy; every conclusion reviewable

项目孵化 — 小步验证，分段给钱Incubation — prove small, fund in stages

照搬服务小微企业的“小步快跑”：可行性过会 → 小规模验证 → 条件具备再放大。

Our small-business playbook: feasibility gate, small-scale validation, scale-up only when earned.

立项可行性门槛与过会标准Feasibility thresholds and review standards
小规模验证指标与周期Small-scale validation metrics and timelines
放大条件与止损线Scale-up conditions and stop-loss lines

🔗 凭什么做医药：老能力 → 新场景🔗 Why us: proven skills, new arena

市场调研 → 适应症规模与支付意愿测算Market research → indication sizing & willingness-to-pay
可行性分析 → 医药立项过会依据Feasibility analysis → project approval basis
成本收入模型 → 研发资金与融资规划Cost-revenue models → R&D funding plans
治理与风控 → 合规体系与信息披露Governance & risk → compliance and disclosure

🧭 怎么推进：三阶段路线🧭 How we advance: three phases

阶段一 · 桌面研究：跟踪方向、积累判断，不投钱Phase 1 · Desk research: track and learn, no capital at risk
阶段二 · 小步验证：小规模试点，验证假设与成本Phase 2 · Small pilots to test theses and costs
阶段三 · 条件放大：团队、资金、合规就绪后再谈规模Phase 3 · Scale only when team, funding and compliance are ready
全程设退出标准，任何阶段都可以停Exit criteria throughout; we can stop at any gate

⚠️ 重要说明：上述方向为公司拟关注和探索的领域，不代表已形成成熟产品、临床项目、商业化收入或监管批准。公司尚未对任何产品、技术、审批、融资或回报作出保证。本页关于未来的表述属前瞻性陈述，实际结果可能因市场、资金、团队、合作与监管等因素产生重大差异，不构成证券发行、投资建议或收益承诺。⚠️ Disclosure: areas above are exploratory only and do not imply mature products, clinical programs, revenue or approvals. No guarantee on products, technology, approvals, financing or returns. Forward-looking statements subject to material risks. Nothing herein is an offer or investment advice.

董事会Board of Directors

资本与产业双线带队的董事会A board spanning capital markets and industry

董事会成员的公开履历覆盖纳斯达克上市公司治理与生物制药研发体系，代表性资本市场案例可参考 spacglobal.com。

The board's public track record spans Nasdaq-listed company governance and biopharma R&D; representative capital-markets cases are showcased at spacglobal.com.

Qi GongQi Gong

董事长Chairwoman

纳斯达克 Quartzsea（QSEA）董事长兼首席执行官、首席财务官；QuasarEdge（QRED）董事长兼首席执行官、首席财务官；Yotta（YOTA）、Quetta（QETA）、Quantumsphere（QUMS）独立董事。美国华尔街上市融资集团及美国信息科技创始人，合肥工业大学毕业，总统志愿服务奖得主。

Chairwoman, CEO & CFO of Nasdaq-listed Quartzsea (QSEA); Chairwoman, CEO & CFO of QuasarEdge (QRED); independent director of Yotta (YOTA), Quetta (QETA) and Quantumsphere (QUMS). Founder of the American Wall Street Listed Group and American Information Technology Inc.; Hefei University of Technology graduate; recipient of the President's Volunteer Service Award.

Pen LanPen Lan

董事Director

董事会成员。详细简介即将公布。

Member of the board. Full bio coming soon.

Keejong ChangKeejong Chang

董事Director

可蓝赛生物医药（上海）董事长兼首席技术官；25年以上生物制药研发与产业化经验；加州大学河滨分校生物化学博士；3项美国专利、1项欧洲专利，发表学术论文29篇以上。

Chairman & CTO of Keycell Lines Biopharmaceutical (Shanghai); 25+ years across drug discovery, biologics and cell/gene platforms; Ph.D. in Biochemistry, UC Riverside; inventor on 3 U.S. and 1 European patent; 29+ scientific publications.

CPLBIOPHARMAINC.

让每一分钱都花得值得。
物有所值 · 物超所值Every dollar well spent.
Value delivered, value exceeded.